ArticleNeuroscience2011
Low and high affinity dopamine transporter inhibitors block dopamine uptake within 5 sec of intravenous injection.
Article in Neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Monoamine Transporters in Drugs of Abuse: Insights from Fast Scan Cyclic Voltammetry.Advances in neurobiology · 2025Review
- Effectiveness and Relationship between Biased and Unbiased Measures of Dopamine Release and Clearance.ACS chemical neuroscience · 2022Article
- A New Method for the Visualization of Living Dopaminergic Neurons and Prospects for Using It to Develop Targeted Drug Delivery to These Cells.International journal of molecular sciences · 2022Article
- Distinct roles for dopamine clearance mechanisms in regulating behavioral flexibility.Molecular psychiatry · 2021Article
- Spontaneous Formation of Melanin from Dopamine in the Presence of Iron.Antioxidants (Basel, Switzerland) · 2020Article
- Corticotropin releasing factor, but not alcohol, modulates norepinephrine release in the rat central nucleus of the amygdala.Neuropharmacology · 2020Article
- Methamphetamine increases dopamine release in the nucleus accumbens through calcium-dependent processes.Psychopharmacology · 2020Article
- Allopregnanolone Decreases Evoked Dopamine Release Differently in Rats by Sex and Estrous Stage.Frontiers in pharmacology · 2020Article
- Effects of ( R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell.ACS chemical neuroscience · 2019Article
- Cholinergic Interneurons Underlie Spontaneous Dopamine Release in Nucleus Accumbens.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Article
- Reinforcing Doses of Intravenous Cocaine Produce Only Modest Dopamine Uptake Inhibition.ACS chemical neuroscience · 2017Article
- Cross-talk between the epigenome and neural circuits in drug addiction.Progress in brain research · 2017Review
- Modafinil Activates Phasic Dopamine Signaling in Dorsal and Ventral Striata.The Journal of pharmacology and experimental therapeutics · 2016Article
- Hypocretin/Orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by hypocretin receptor 1.ACS chemical neuroscience · 2015Article
- Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: implications for the pathogenesis of free radical-induced neurodegenerative disorders.Psychopharmacology · 2013Article
- Examining the complex regulation and drug-induced plasticity of dopamine release and uptake using voltammetry in brain slices.ACS chemical neuroscience · 2013Review
- Daily monitoring of dopamine efflux reveals a short-lasting occlusion of the dopamine agonist properties of d-amphetamine by dopamine transporter blockers GBR 12909 and methylphenidate.ACS chemical neuroscience · 2013Article
- Effects of the histamine H₁ receptor antagonist and benztropine analog diphenylpyraline on dopamine uptake, locomotion and reward.European journal of pharmacology · 2012Article
- Optogenetically-induced multimerization of the dopamine transporter increases uptake and trafficking to the plasma membrane.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Extensive evidence suggests that the reinforcing effects of cocaine involve inhibition of dopamine transporters (DAT) and subsequent increases in dopamine (DA) levels in the striatum. We have previously reported that cocaine inhibits the DAT within 4-5 s of i.v. injection, matching the temporal profile of the behavioral and subjective effects of cocaine. Intravenous injection of GBR-12909, a high affinity, long-acting DAT inhibitor, also inhibits DA uptake within 5 s. Given that high affinity, long-acting drugs are considered to have relatively low abuse potential, we found it intriguing that GBR-12909 had an onset profile similar to that of cocaine. To further explore the onset kinetics of both low and high affinity DAT inhibitors, we examined the effects of i.v. cocaine (1.5 mg/kg), methylphenidate (1.5 mg/kg), nomifensine (1.5 mg/kg), GBR-12909 (1.5 mg/kg), PTT (0.5 mg/kg), and WF23 (0.5 mg/kg) on electrically-evoked DA release and uptake in the nucleus accumbens core. Results indicate that all of the DAT inhibitors significantly inhibited DA uptake within 5 s of injection. However, the timing of peak uptake inhibition varied greatly between the low and high affinity uptake inhibitors. Uptake inhibition following cocaine, methylphenidate, and nomifensine peaked 30 s following injection. In contrast, peak effects for GBR-12909, PTT, and WF23 occurred between 20 and 60 min following injection. These observations suggest that the initial onset for i.v. DAT inhibitors is extremely rapid and does not appear to be dictated by a drug's affinity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.